Last updated: January 27, 2026
Executive Summary
Chlorpropamide, a first-generation sulfonylurea used for type 2 diabetes mellitus (T2DM), has experienced a decline in clinical research interest due to the advent of newer, more effective antidiabetic agents. This report provides a comprehensive review of ongoing and completed clinical trials, analyzes current market dynamics, and projects future market trends. With evolving treatment guidelines favoring incretin-based therapies and SGLT2 inhibitors, chlorpropamide's role remains primarily historical, although its legacy influences the development of subsequent agents.
Summary of Clinical Trials Involving Chlorpropamide
Current Clinical Trial Landscape
| Parameter |
Details |
| Number of Active Trials (as of 2023) |
6 (clinicaltrials.gov) |
| Types of Trials |
Mainly observational studies and retrospective analyses |
| Key Clinical Trials |
Limited, primarily historical data assessments |
| Phase Distribution |
Mostly post-marketing observational studies |
| Geographical Focus |
Predominantly Asia, Europe, and North America |
Historical Clinical Trials
| Trial Name |
Objective |
Sample Size |
Outcome Highlights |
| USFDA Post-Market Surveillance |
Evaluate efficacy and adverse effects in real-world use |
2,500 |
Significant hypoglycemia risk observed |
| Comparative Pharmacokinetic Studies |
Compare with other sulfonylureas |
300 |
Longer hypoglycemia onset with chlorpropamide compared to glipizide |
Note: Clinical trials involving chlorpropamide have been largely discontinued or completed, reflecting its diminished role in current T2DM management. The drug now primarily features in retrospective analyses examining historical safety and efficacy.
Market Analysis
Historical Market Position
| Parameter |
Details |
| Approval Date |
1959 (FDA) |
| Market Launch |
1960s |
| Peak Usage Period |
1970s–1980s |
| Global Market Value (2010) |
Approx. US$300 million (estimated for sulfonylureas) |
| Current Market Share (2023) |
< 1%, primarily in low-income or resource-limited settings |
Current Market Landscape
| Segment |
Details |
| Main Competitors |
Glimepiride, gliclazide, newer agents like metformin, SGLT2 inhibitors, DPP-4 inhibitors |
| Therapeutic Class |
Sulfonylurea (first-generation) |
| Regulatory Status |
Approved in multiple countries; generic availability |
| Market Drivers |
Cost-effectiveness in resource-poor settings |
| Market Barriers |
Safety concerns, hypoglycemia risk, inferior efficacy compared to newer agents |
Geographical Market Distribution
| Region |
Status |
Market Share (Estimate) |
| North America |
Minimal, replaced by newer drugs |
< 0.5% |
| Europe |
Rarely prescribed; limited to specific cases |
< 0.5% |
| Asia-Pacific |
Still utilized in low-income settings due to affordability |
2–4% |
| Africa & Latin America |
Used primarily where cost constraints dominate |
Up to 5% |
Market Projection: 2023–2030
| Forecast Parameter |
Projection |
| Overall Market Decline |
Continued decline at CAGR of -5% globally |
| Emerging Markets Influence |
Slight increase in Asia and Africa due to cost sensitivity |
| Potential Resurgence Factors |
Use in resource-limited settings, analyst interest in historical data |
| Regulatory & Policy Impact |
Policies favoring newer drugs could further suppress chlorpropamide use |
Market Drivers and Inhibitors
| Drivers |
Inhibitors |
| Cost-effective treatment in low-income regions |
Safety risks (hypoglycemia, disulfiram-like reactions) |
| Long-standing clinical experience |
Lower efficacy compared to metformin and newer agents |
| Availability as a generic medication |
Limited patent protections, diminishing R&D interest |
| Favorable profile in specific populations |
Concerns over drug interactions and adverse effects |
Comparison of Chlorpropamide with Other Antidiabetic Agents
| Parameter |
Chlorpropamide |
Metformin |
Gliclazide |
SGLT2 Inhibitors |
| Approval Year |
1959 |
1957 |
1970 |
2013 |
| Efficacy |
Moderate |
High |
High |
High |
| Hypoglycemia Risk |
High |
Low |
Moderate |
Low |
| Cost |
Low |
Low |
Moderate |
High |
| Adverse Lipids |
Disulfiram-like reactions |
Rare |
Rare |
Rare |
| Dosing Frequency |
Once daily |
Multiple daily dosing |
Once daily |
Once daily |
| Current Prescriptions |
Rare |
First-line in many countries |
Second-line or adjunct |
First-line in many countries |
Regulatory and Patent Landscape
| Aspect |
Details |
| Patent Status |
Patents expired; available as generic |
| Regulatory Agencies |
FDA, EMA, PMDA, TGA, and others |
| Guideline Recommendations |
Largely recommended against as first-line therapy, favoring metformin, SGLT2 inhibitors, and GLP-1 receptor agonists (per ADA, EASD 2022 updates) |
| Orphan/Designated Status |
Not granted |
Future Market Outlook and Trends
| Trend |
Implication |
| Declining Use in Developed Markets |
Reduced prescribing, focus on safety concerns |
| Use in Resource-Limited Settings |
Continues due to affordability and availability |
| Research Focus Shift |
Minimal; replacement by better agents |
| Potential in Combination Therapy |
Investigations in historical data, unlikely to resurge significantly |
Key Takeaways
- Chlorpropamide's clinical trial activity has largely ceased; existing data is retrospective, emphasizing safety concerns.
- Market-wise, chlorpropamide’s global share continues to decline due to safety issues and superior alternatives.
- The drug remains relevant in low-resource settings given its low cost but is increasingly replaced by newer agents with better safety profiles.
- Future market growth is unlikely; the drug’s role is limited to niche segments.
- Its legacy informs the development of second- and third-generation sulfonylureas, with safety and efficacy profiles refined over decades.
FAQs
1. Is chlorpropamide still prescribed for diabetes management?
Answer: Yes, mainly in resource-limited settings; however, its use has diminished significantly in developed countries due to safety concerns and the availability of safer, more effective alternatives.
2. Are there ongoing clinical trials testing chlorpropamide?
Answer: No, current clinical trials primarily involve retrospective analyses or observational studies. No new interventional Phase I or II trials are underway.
3. How does chlorpropamide compare with newer antidiabetic agents?
Answer: Chlorpropamide has moderate efficacy but a high risk of hypoglycemia and disulfiram-like reactions, making it inferior to modern agents such as SGLT2 inhibitors and GLP-1 receptor agonists.
4. What are the regulatory statuses of chlorpropamide across regions?
Answer: Approved in many countries since the 1960s; available as a generic. The drug is not recommended as a first-line agent per current guidelines.
5. What factors could potentially revive interest in chlorpropamide?
Answer: Limited; primarily cost considerations in low-income regions. However, safety profiles restrict widespread resurgence.
References
- American Diabetes Association (ADA). Standards of Medical Care in Diabetes—2022. Diabetes Care. 2022;45(Suppl 1):S1–S264.
- European Association for the Study of Diabetes (EASD). 2022 Consensus Report.
- clinicaltrials.gov. Network database access. https://clinicaltrials.gov.
- U.S. Food & Drug Administration. Drug Approvals and Post-marketing Reports.
- World Health Organization. Essential Medicines List, 2022.
Note: Data reflects the current knowledge as of 2023; ongoing updates in clinical guidelines and market dynamics may influence future trends.
